Transchem

Which are the latest news on Transchem?

How big is Transchem?

As of 10th June, Transchem Ltd has a market capitalization of 373.00 Cr, with recent net sales of 0.00 Cr and a net profit of 4.29 Cr. Shareholder's funds are 79.32 Cr, and total assets amount to 79.73 Cr as of March 2025.

As of 10th June, Transchem Ltd has a market capitalization of 373.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Transchem reported Net Sales of 0.00 Cr and a Net Profit of 4.29 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, with Shareholder's Funds amounting to 79.32 Cr and Total Assets of 79.73 Cr.

Who are in the management team of Transchem?

The management team of Transchem includes Bina Shah (Chairperson), Neerav Merchant (Independent Director), Neeraja Karandikar (Company Secretary & Compliance Officer), Mirza Saeed Kazi (Director), and Mahesh Suresh Rananavre (Whole-time Director).

The management team of Transchem includes the following individuals:<BR><BR>1. **Bina Shah** - Chairperson<BR>2. **Neerav Merchant** - Independent Director<BR>3. **Neeraja Karandikar** - Company Secretary & Compliance Officer<BR>4. **Mirza Saeed Kazi** - Director<BR>5. **Mahesh Suresh Rananavre** - Whole-time Director<BR><BR>If you need more details about their roles or responsibilities, feel free to ask!

Who are the peers of the Transchem?

Transchem's peers include Bafna Pharma, Haleos Labs, Albert David, Valiant Laborato, Medico Remedies, Medicamen Biotec, Trident Lifeline, Zenotech Lab, and Infinium Pharma. Transchem has a 1-year return of 605.82%, outperforming its peers, with Bafna Pharma showing the highest return at 135.33%.

Peers: The peers of Transchem are Bafna Pharma., Haleos Labs Limi, Albert David, Valiant Laborato, Medico Remedies, Medicamen Biotec, Trident Lifeline, Zenotech Lab., and Infinium Pharma.<BR><BR>Quality Snapshot: Excellent management risk is observed at Albert David and Medicamen Biotec, while Average management risk is found at Haleos Labs Limi, Transchem, Trident Lifeline, Zenotech Lab., and the rest. Below Average management risk is noted for Bafna Pharma., Valiant Laborato, Medico Remedies, and Infinium Pharma. Growth is classified as Excellent for Trident Lifeline, Good for Valiant Laborato and Zenotech Lab., and Below Average for Bafna Pharma., Haleos Labs Limi, Albert David, Medico Remedies, Transchem, Medicamen Biotec, and Infinium Pharma. Capital Structure is Excellent for Albert David and Medicamen Biotec, Good for Bafna Pharma., Medico Remedies, and Trident Lifeline, while Below Average is seen at Haleos Labs Limi, Valiant Laborato, Transchem, Zenotech Lab., and Infinium Pharma.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Bafna Pharma. at 135.33%, while the lowest is Albert David at -18.28%. Transchem's own 1-year return of 605.82% significantly surpasses both. Additionally, peers with negative six-month returns include Haleos Labs Limi, Medicamen Biotec, Trident Lifeline, Zenotech Lab., and Infinium Pharma.

Why is Transchem Ltd falling/rising?

As of 11-Jun, Transchem Ltd's stock price is declining, currently at 275.20, down 4.99%. Despite a strong yearly performance, recent trends show a significant short-term downturn and reduced investor interest.

As of 11-Jun, Transchem Ltd's stock price is falling, currently at 275.20, which reflects a decrease of 14.45 or 4.99%. The stock has been underperforming, having lost 9.73% over the last two days and opened with a loss of 4.99% today. Additionally, it has underperformed its sector by 5.41%. <BR><BR>Investor participation has also declined, with delivery volume dropping by 62.76% compared to the 5-day average, indicating reduced interest in trading the stock. Despite the stock's strong performance over longer periods, such as a 605.82% increase over the past year, the recent trends suggest a significant downturn in the short term. The stock is currently trading below its 5-day moving average, although it remains above the 20-day, 50-day, 100-day, and 200-day moving averages. This combination of factors contributes to the current decline in Transchem Ltd's stock price.

What does Transchem do?

Transchem Ltd is a Micro Cap company in the Pharmaceuticals & Biotechnology industry, originally incorporated in 1976, with a recent net profit of 2 Cr for Q1 2026. The company has shifted from mushroom production and currently has a market cap of INR 373 Cr.

Overview:<BR>Transchem Ltd operates in the Pharmaceuticals & Biotechnology industry and is classified as a Micro Cap company.<BR><BR>History:<BR>Transchem Limited was incorporated as a private limited company on 18 November 1976 and converted into a public limited company on 13 April 1992. The company initially engaged in mushroom production but has not been operational in this area for several years due to changes in the international horticulture scenario. The latest reported net profit is 2 Cr for the quarter ending March 2026.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: N/A<BR>Most recent Net Profit: 2 Cr (Quarterly Results - Mar 2026)<BR>Market-cap value: INR 373 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 83.00<BR>Industry P/E: 34<BR>Dividend Yield: 0.00%<BR>Debt Equity: -0.01<BR>Return on Equity: 5.30%<BR>Price to Book: 4.59<BR><BR>Contact Details:<BR>Address: 304 Ganatra Estate, Pokhran Road No.1 Khopat Thane (West) Maharashtra : 400601<BR>Phone: 91-22-25477077<BR>Email: secretaryu@transchem.net<BR>Website: http://www.transchem.net

Are Transchem Ltd latest results good or bad?

Transchem Ltd's latest results are concerning, showing a 100% decline in net sales to ₹0.00 crore while reporting a net profit of ₹2.09 crores largely due to non-operational income. This indicates significant operational challenges and a troubling shift away from its core pharmaceutical manufacturing business.

Transchem Ltd's latest results indicate a troubling situation for the company. In the fourth quarter of FY26, the company reported net sales of ₹0.00 crore, which reflects a complete collapse in revenue compared to ₹2.42 crores in the same quarter last year, marking a 100% decline year-on-year. This suggests that Transchem has effectively ceased its operations as a pharmaceutical manufacturer.<BR><BR>On a more positive note, the company did report a net profit of ₹2.09 crores for the same quarter, which is a significant increase of 186.30% year-on-year from ₹0.73 crores in Q4 FY25. However, this profit is largely attributed to other income, which surged to ₹3.70 crores, indicating that the company is relying on non-operational income rather than its core business activities.<BR><BR>The return on equity stands at a low 4.56%, and the overall financial performance is concerning, with operating losses before considering other income. The company's transformation from a manufacturing entity to what appears to be an investment vehicle raises serious questions about its future viability as a pharmaceutical business.<BR><BR>In summary, while there is a notable increase in net profit, the complete absence of sales and reliance on non-operating income paints a grim picture for Transchem Ltd. The results can be classified as bad, reflecting significant operational challenges and a fundamental shift in the company's business model.

Should I buy, sell or hold Transchem Ltd?

When is the next results date for Transchem Ltd?

The next results date for Transchem Ltd is 05 May 2026.

The next results date for Transchem Ltd is scheduled for 05 May 2026.

How has been the historical performance of Transchem?

Transchem's historical performance shows significant growth, with net sales and total operating income reaching 2.63 Cr in March 2025, up from 0.41 Cr in March 2024. Despite increased expenditures, the company reported improved profits, with profit after tax rising to 5.23 Cr and a net cash inflow of 42 Cr, indicating a positive trend in revenue and profitability.

Answer:<BR>The historical performance of Transchem shows a significant increase in net sales, reaching 2.63 Cr in March 2025, up from 0.41 Cr in March 2024, and starting from zero in previous years. Total operating income also rose to 2.63 Cr in March 2025, reflecting the same trend. However, total expenditure increased to 4.09 Cr in March 2025, leading to an operating profit (PBDIT) of 7.07 Cr, which is an improvement from 5.67 Cr in March 2024. The profit before tax for March 2025 was 7.06 Cr, up from 5.65 Cr in the prior year, while profit after tax reached 5.23 Cr, compared to 4.20 Cr in March 2024. The earnings per share (EPS) increased to 4.27 in March 2025 from 3.43 in March 2024. <BR><BR>In terms of assets and liabilities, total assets grew to 79.73 Cr in March 2025, up from 76.32 Cr in March 2024, with total liabilities also increasing to 79.73 Cr. The company maintained a stable equity capital of 12.24 Cr across the years. Cash flow from operating activities improved significantly to 36 Cr in March 2025, compared to a negative 39 Cr in March 2024, contributing to a net cash inflow of 42 Cr in March 2025, a notable recovery from a net outflow of 34 Cr in the previous year. Overall, Transchem's financial performance indicates a positive trend in revenue generation and profitability, despite rising expenditures.<BR><BR>Breakdown:<BR>Transchem's financial performance has shown a remarkable upward trajectory in net sales, which surged to 2.63 Cr in March 2025 from 0.41 Cr in March 2024, marking a significant recovery from previous years where sales were non-existent. Total operating income mirrored this growth, reaching 2.63 Cr in March 2025. Despite the increase in total expenditure to 4.09 Cr, the company reported an operating profit (PBDIT) of 7.07 Cr, up from 5.67 Cr in the prior year, indicating improved operational efficiency. Profit before tax also rose to 7.06 Cr, while profit after tax reached 5.23 Cr, reflecting a healthy increase from 4.20 Cr in March 2024. The earnings per share (EPS) rose to 4.27, further showcasing the company's profitability. On the balance sheet, total assets increased to 79.73 Cr, with total liabilities matching this figure, indicating a stable financial position. Cash flow from operating activities saw a significant turnaround, resulting in a net cash inflow of 42 Cr in March 2025, a stark contrast to the previous year's outflow. Overall, Transchem's financial metrics indicate a positive trend in both revenue and profitability, despite rising costs.

Is Transchem overvalued or undervalued?

As of April 25, 2023, Transchem is considered a risky but undervalued investment with favorable valuation metrics, including a PE Ratio of 9.28, compared to its peers, despite recent underperformance against the Sensex.

As of 25 April 2023, the valuation grade for Transchem has moved from does not qualify to risky. The company is currently considered undervalued based on its financial metrics. Key ratios include a PE Ratio of 9.28, a Price to Book Value of 0.63, and a PEG Ratio of 0.39, indicating potential for growth relative to its price. <BR><BR>In comparison to its peers, Transchem's valuation appears favorable against Sun Pharma's PE Ratio of 35.25 and Divi's Lab's PE Ratio of 79.33, both of which are classified as expensive. Additionally, Transchem's EV to EBITDA ratio of -32.72 stands out as a notable outlier, suggesting significant challenges in profitability relative to its enterprise value. Despite recent underperformance against the Sensex, with a year-to-date return of -22.30% compared to the Sensex's 5.59%, the overall valuation metrics suggest that Transchem may present an attractive opportunity for investors.

What is the technical trend for Transchem?

As of June 2, 2025, Transchem's technical trend has shifted to mildly bearish, influenced by daily moving averages and weekly Bollinger Bands indicating bearish conditions, despite some mildly bullish signals from the weekly MACD and KST.

As of 2 June 2025, the technical trend for Transchem has changed from sideways to mildly bearish. The current stance is mildly bearish, driven primarily by the daily moving averages indicating a bearish trend and the weekly Bollinger Bands also signaling bearish conditions. While the weekly MACD and KST are mildly bullish, they are offset by the overall bearish indicators. The stock has experienced a significant decline year-to-date, further supporting the bearish outlook.

Who are the top shareholders of the Transchem?

The top shareholders of Transchem are Priyanka Finance Private Limited with 40.11%, followed by Smit Capital Services Private Limited at 11.02%. Individual investors own 24.69%, with no pledged promoter holdings or shares held by mutual funds or foreign institutional investors.

The top shareholders of Transchem include Priyanka Finance Private Limited, which holds the largest stake at 40.11%. Following that, Smit Capital Services Private Limited is the highest public shareholder with an 11.02% ownership. Additionally, individual investors collectively hold 24.69% of the company's shares. Notably, there are no pledged promoter holdings, and the company does not have any mutual funds or foreign institutional investors holding shares.

Has Transchem declared dividend?

No Dividend History Available